NewsRoom Articles - Page 72 of 144 - PsychedelicNewsWire (PNW)

FridayOct 08, 2021 11:41 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operations The company appoints Dr. Geoff Varty as head of research and development Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team. Cybin has named Dr. Amir Inamdar as chief medical…

FridayOct 08, 2021 11:20 am

Psychedelic Substances May Decrease Shame Among Individuals Who Suffered Mistreatment as Children

A new study, reported in the “Chronic Stress” journal, has found that the use of psychedelic substances is linked to decreased levels of internalized shame and PTSD symptoms in adults who underwent maltreatment as children. The author of the study, CJ Healy, who is a PhD student at the New School for Social Research, stated that while there existed various studies on the therapeutic effects of psychedelics, very few looked into the substances’ potential use in nonclinical settings. Healy explained that most individuals across the globe who were using psychedelics to heal themselves were taking the them in nonclinical settings,…

ThursdayOct 07, 2021 9:30 am

Grand Rapids City Council Approves Psychedelics Decriminalization Measure

Earlier last week, another city in the state of Michigan passed a measure that called for the decriminalization of psychedelics, including ayahuasca and psilocybin. The measure doesn’t meet activists’ expectations, however, because it doesn’t change any enforcement practices in the city. Instead, the initiative stipulates that the city commission and mayor support federal, state and local legislative efforts to decriminalize entheogenic fungi and plants as well as plant-based compounds that are classified under the Controlled Substances Act. The measure, which the city commission of Grand Rapids approved in a 5 to 2 vote, states that individuals who seek to improve…

WednesdayOct 06, 2021 1:19 pm

Former Congresswoman Backs the Use of Psilocybin in Treating Alcohol Use Disorder

Former Congresswoman Mimi Walters (R) has been proclaiming the therapeutic benefits of psychedelic substances. In a recent interview, Walters revealed that somebody close to her family had been struggling to overcome alcohol use disorder while she talked about a legislation that would legalize the possession of various psychedelics. The former Republican congresswoman, who left Congress in 2019, explained that the close family friend had been able to recover from the disorder with the help of psilocybin after participating in a study conducted at New York University. Various studies have shown that some psychedelics may be effective in treating conditions such…

TuesdayOct 05, 2021 11:00 am

What Investors Consider Before Investing in Psychedelic Startup Companies

In the last few years, venture-capital funds have played a big role in facilitating the establishment of psychedelic firms. To do this, those VC companies have had to go through many business models and pitches. Research shows that the top investors in the psychedelics industry since the beginning of last year are Neo Kuma, Palo Santo and Noetic Fund. They have injected the most capital into psychedelic startup firms. In total, the three companies deployed roughly $85 million into these startups. Today, we’ll look at some of the variables these companies took into consideration as well as the qualities they…

MondayOct 04, 2021 2:00 pm

NIDA Awards Grant for Research on Potential of Psilocybin in Treating Cigarette Addiction

The National Institute on Drug Abuse is financing research on the use of magic mushrooms in managing cigarette addiction. The top federal drug agency recently awarded the grant to researchers from the University of Alabama at Birmingham, New York University and Johns Hopkins University to investigate how psilocybin could help individuals quit smoking cigarettes. Last week, Matthew Johnson, a professor at Johns Hopkins University, revealed that the researchers had been awarded the grant, noting that he believed that it was the first grant from the federal government in more than five decades to directly study the therapeutic benefits of a…

FridayOct 01, 2021 12:15 pm

Researchers Develop Statistical Model That Can Characterize Ketamine’s Effects on the Brain

Researchers from the Massachusetts General Hospital and the Picower Institute for Learning and Memory at MIT have developed a statistical model that can characterize how ketamine affects an individual’s brain. The research, which was published in “PLOS Computational Biology,” found that ketamine produced different effects, which means that to improve patient outcomes and better understand ketamine, a ketamine-specific model was needed. This is why the researchers designed a model based on rhythm measurements from two animal subjects and nine human subjects. The model defines the characteristic states of brain activity that occur when an individual is under ketamine anesthesia. In…

ThursdaySep 30, 2021 2:15 pm

Phantom Limb Pain: Causes and How a Physical Therapist May Help

When an individual’s leg or arm is traumatically lost or surgically amputated, they may experience a persistent sensation indicating that the lost limb is still present. This phantom sensation, which may be unpleasant or painful, is commonly called phantom limb pain. Estimates show that while about 80% of individuals who have undergone amputations will experience this type of pain, the pain persists only about 20% of the time, with some of these individuals experiencing this pain even two years after the amputation procedure. While it doesn’t result from conditions such as depression and psychiatric stress, phantom limb pain may be…

ThursdaySep 30, 2021 10:59 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803 During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical…

WednesdaySep 29, 2021 11:30 am

Why Nuanced Approach in Dealing with Mental Health Issues, Specifically Depression, Is Important

A couple of decades ago, talking about mental health issues in the public was an unspoken taboo. Research on mental health conditions hadn’t come as far as today, and society’s view of mental health wasn’t as open, which led to many people suffering in silence, scared to speak up or seek help. Today discussing how conditions are approached and treated is much more open. Among the most common mental health conditions is depression, a serious ailment that negatively affects how an individual feels, acts and thinks. The disorder causes a loss of interest in activities an person once enjoyed as…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050